Precipio, Inc. PRPO 深 沪
等待开盘 04-01 09:30:00 美东时间
25.00
+1.105
+4.62%
华盛通- 最 高25.00
- 今 开24.31
- 成交量 1.19万股
- 最 低 23.705
- 昨 收 23.895
- 总市值 4380.02万
- 52周最高 29.5299
- 市盈率 静 --
- 换手率 0.68%
- 52周最低 5.09
- 委 比 -45.02%
- 总股本 175.20万
- 历史最高 8448.00
- 量 比 0.31
- 振 幅 5.42%
- 历史最低 3.90
- 每 手 1
- 风险率 6.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Precipio Announces Q4 and year-end 2025 Shareholder Update Call
Precipio, Inc., a specialty cancer diagnostics company, will host a conference call on April 2nd, 2026, at 5:00 PM ET to discuss Q4 and year-end 2025 updates. Participants can join by dialing 646.307.1865 and requesting the Precipio Inc. conference call. Pre-submitted questions can be emailed to investors@precipiodx.com. A replay will be available via Precipio's Investor page within 24 hours. Precipio focuses on improving cancer diagnostics to re...
03-12 21:00
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
Precipio, Inc. has launched the first and only BCR::ABL1 assay that simultaneously detects and quantifies all four clinically relevant isoforms, setting a new standard for monitoring Chronic Myeloid Leukemia (CML). Unlike existing assays, Precipio’s Bloodhound BCR::ABL1 assay provides full quantification of all four isoforms, enabling comprehensive disease monitoring and early detection of relapse. With high sensitivity, it detects changes as low...
03-10 13:00
Precipio Q4 2025 Preliminary Revenue $6.7M, An Increase Of 23% From $5.4M YoY
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025.Below are some of the key financial performance metrics
02-25 22:33
Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
Illustrating strong financial performance in 2025, Precipio Inc. reported a 30% YoY revenue increase from $18.5M to $24.0M, with Q4-2025 revenue at $6.7M (23% YoY growth). Adjusted EBITDA turned positive, reaching $0.95M in Q4 and $1.23M for the year, up from losses in 2024. The company also achieved $368K positive operating cash flow in Q4 and $688K annually, reflecting improved financial stability. CEO Ilan Danieli highlighted the importance of...
02-25 14:30
Precipio Takes Major Steps Toward a Clean Balance Sheet
Specialty cancer diagnostics company Precipio, Inc. has cleaned up its balance sheet with two major achievements: repaying a $1.1 million advance from Change Healthcare and exercising all financial warrants. The company now only holds a minor $80,000 loan and 10,000 warrants for vendors. CEO Ilan Danieli highlights reduced financial risk and ongoing efforts to grow the business and create shareholder value.
01-15 14:00
Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
Precipio, Inc. will present findings from a joint study with Memorial Sloan Kettering Cancer Center at the ASH Meeting. The study, evaluating Precipio’s BCR::ABL1 assay, analyzed 895 patient samples and demonstrated superior performance compared to other leading platforms, positively impacting patient care and improving laboratory workflows. The presentation will occur on December 8th in Orlando, Florida. Precipio is a cancer diagnostics company ...
2025-12-05 15:00
Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact
Precipio, Inc. reported a limited unauthorized access to a specific data folder in its secure cloud environment, which did not impact operations, patient care, or financial data. The company promptly responded by securing systems, resetting passwords, and engaging cybersecurity experts. The accessed files contained historical operational information with no sensitive patient or financial data. Precipio's systems remain stable, and the incident is...
2025-12-04 13:00
Precipio Announces its Q3-2025 Financial Results
Precipio, Inc. reported Q3-2025 financial results, with revenues reaching $6.8M, a 30% YoY increase and 20% QoQ growth. Adjusted EBITDA was $469K, up $369K YoY and $500K QoQ, turning positive. Cash flow improved by $433K QoQ, from a burn of ($148K) to $285K generated. Pathology Services Division revenue rose 20% QoQ, while Products Division grew 16% QoQ. CEO Ilan Danieli highlighted operational efficiencies and financial discipline driving positi...
2025-11-14 21:30
Precipio Announces Q3-2025 Shareholder Update Call
Precipio, Inc., a specialty cancer diagnostics company, will host its Q3-2025 corporate update conference call on November 17, 2025, at 5:00 PM ET. Participants can join by dialing 800-717-1738 and requesting the Precipio conference call. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available on Precipio's website. The company focuses on improving cancer diagnostics to reduce misdiagnoses, enhance ...
2025-11-04 22:00
Precipio Terminates Its ATM
Specialty cancer diagnostics company Precipio, Inc. has terminated its At-The-Market (ATM) instrument with investment bank Alliance Global Partners (AGP). CEO Ilan Danieli stated that the company is in a stronger financial position now, with positive cash flow and increased cash reserves, making the ATM tool unnecessary for capital raises. This move reflects management's commitment to responsible capital management and creating shareholder value.
2025-09-02 14:00
